Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-Linked Retinoschisis (Globe Newswire)

UF startup Atsena Therapeutics announced that dosing is complete in adults enrolled in Part B of the LIGHTHOUSE study, the Phase I/II/III clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Optym Launches LoadAi, Bringing Real-Time Decision Intelligence to Truckload Dispatching (Cision PR Web)

UF startup Optym announced the launch of LoadAi, an AI-powered operations platform built to help truckload carriers reduce empty miles, optimize dispatch decisions, and scale planner productivity across their networks.
LightPath Technologies Awarded $22.1 Million Follow-On Purchase Order To Supply Advanced Infrared Camera Systems (PR Newswire)

UF startup LightPath Technologies, Inc., announced it has secured $22.1 million in follow-on purchase orders with a leading global technology customer related to the supply of advanced infrared camera systems in CY 2027.
LightPath Technologies Secures $18.2 Million Purchase Order To Supply Advanced Infrared Camera Systems (PR Newswire)

UF startup LightPath Technologies announced it has secured an $18.2 million purchase order with a leading global technology customer related to the supply of advanced infrared camera systems in CY 2026.
NovaBone To Unveil First-of-Its-Kind Bioactive Wedge at AOFAS 2025 Annual Meeting in Savannah (PR Newswire)

UF startup NovaBone, a pioneer in synthetic bone graft technologies, will showcase its Bioactive Pre-contoured Wedge (BPW) at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting.
Gene Therapy Specialist Kriya Raises $313M (Bio Space)

UF startup Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
SandboxAQ and iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery for Glioblastoma

SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults.
Technical Toolboxes Announces Strategic Growth Investment From BVP Forge To Accelerate Innovation in Energy Infrastructure Software

UF startup Technical Toolboxes, a leading provider of advanced engineering and maintenance software for energy infrastructure, announced a strategic growth investment from BVP Forge.
Atsena Therapeutics Announces Alignment With FDA on Regulatory Pathway to Approval for ATSN-201 in X-Linked Retinoschisis (XLRS)

UF startup Atsena Therapeutics received FDA approval to expand its Phase 1/2 LIGHTHOUSE study of ATSN-201 into a pivotal Phase 1/2/3 trial to support a BLA submission for treating X-linked retinoschisis (XLRS).